{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:19:49Z","timestamp":1790918389509,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.clinbiochem.2018.08.003","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T23:14:11Z","timestamp":1534547651000},"page":"84-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Serum human epididymis protein 4 vs. carbohydrate antigen 125 in ovarian cancer follow-up"],"prefix":"10.1016","volume":"60","author":[{"given":"Simona","family":"Ferraro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Robbiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Tosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Panzeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8253-3630","authenticated-orcid":false,"given":"Anna Maria","family":"Paganoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Panteghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0005","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/jclinpath-2012-201031","article-title":"Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review","volume":"66","author":"Ferraro","year":"2013","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0010","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/IGC.0000000000000218","article-title":"The role of HE4 in ovarian cancer follow-up: a review","volume":"24","author":"Piovano","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0015","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0004563213500657","article-title":"Is serum human epididymis protein 4 ready for prime time?","volume":"51","author":"Ferraro","year":"2014","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","article-title":"HE4: a new potential early biomarker for the recurrence of ovarian cancer","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumour Biol."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0025","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1245\/s10434-013-3347-1","article-title":"HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse","volume":"21","author":"Braicu","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0030","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1007\/s13277-015-4031-9","article-title":"The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study","volume":"37","author":"Nassir","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0035","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.3892\/ol.2016.4533","article-title":"Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer","volume":"11","author":"Steffensen","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194270","article-title":"Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?","volume":"13","author":"Chudecka-G\u0142az","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0045","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1515\/cclm-2017-1176","article-title":"Prognostic value of HE4 in patients with ovarian cancer","volume":"56","author":"Yuan","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0050","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1515\/cclm-2014-0097","article-title":"The importance of individual biology in the clinical use of serum biomarkers for ovarian cancer","volume":"52","author":"Braga","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0055","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cca.2014.08.020","article-title":"Human epididymis proten 4: factors of variation","volume":"438","author":"Ferraro","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0060","author":"NCCN Clinical Practice Guidelines in Oncology"},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0065","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Gynecological cancer intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0070","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1515\/cclm-2015-1142","article-title":"Verification of the harmonization of human epididymis protein 4 assays","volume":"54","author":"Ferraro","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0075","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13048-017-0310-y","article-title":"Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study","volume":"10","author":"Guo","year":"2017","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/annonc\/mdi012","article-title":"Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?","volume":"16","author":"Crawford","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0085","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1515\/cclm-2015-1272","article-title":"Cystatin C provides a better estimate of the effect of glomerular filtration rate on serum human epididymis protein 4 concentrations","volume":"54","author":"Ferraro","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0090","series-title":"Kidney Int Supp","first-page":"1","volume":"3","author":"KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","year":"2013"},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0095","author":"Bartlett"},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0100","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.5301\/jbm.5000251","article-title":"Circulating tumor markers: a guide to their appropriate clinical use. Comparative summary of recommendations from clinical practice guidelines (part 1)","volume":"31","author":"Gion","year":"2016","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0105","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.6004\/jnccn.2013.0142","article-title":"National comprehensive cancer networks. Ovarian cancer, version 2.2013","volume":"11","author":"Morgan","year":"2013","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"Suppl. 6","key":"10.1016\/j.clinbiochem.2018.08.003_bb0110","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0115","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","article-title":"Cisplatin nephrotoxicity: mechanisms and renoprotective strategies","volume":"73","author":"Pabla","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0120","author":"GLOBOCAN"},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0125","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ygyno.2008.01.035","article-title":"Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel\/platinum chemotherapy: a French multicentric study","volume":"109","author":"Riedinger","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0130","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/bjc.2014.75","article-title":"Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients","volume":"110","author":"Wilbaux","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0135","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1054\/bjoc.2001.1787","article-title":"Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemo-therapy","volume":"84","author":"Tuxen","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0140","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1515\/cclm-2017-0954","article-title":"Reply to: Hyperuricemia does not seem to be an independent risk factor for coronary heart disease","volume":"56","author":"Braga","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0145","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1309\/NBA312W0LANRXYH9","article-title":"Performance characteristics of seven automated CA 125 assays","volume":"125","author":"Mongia","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0150","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ygyno.2014.04.003","article-title":"Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development","volume":"133","author":"Wilbaux","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0155","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijgo.2015.09.013","article-title":"Importance of serial CA125 measurements over an absolute cut-off value for the detection of asymptomatic ovarian cancer in high-risk patients","volume":"133","author":"Dilley","year":"2016","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0160","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.12-1-72","article-title":"Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients","volume":"12","author":"Coleman","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0165","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1002\/cncr.23893","article-title":"Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy","volume":"113","author":"Markman","year":"2008","journal-title":"Cancer"},{"issue":"Suppl. 10","key":"10.1016\/j.clinbiochem.2018.08.003_bb0170","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0175","series-title":"69th AACC Annual Scientific Meeting Abstracts","article-title":"Alteration of serum CA125 and HE4 levels in response to chemotherapy in patients with different histological subtypes of ovarian cancer","author":"Wang","year":"2017"},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0180","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1006\/gyno.2001.6432","article-title":"Potential clinical utility of CA-125 in responsive but persistent large-volume ovarian cancer following platinum-based chemotherapy","volume":"83","author":"Markman","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0185","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/gyno.2000.5787","article-title":"Declining CA-125 in an ovarian cancer patient with progression of measurable disease: a rational hypothesis for discordant results","volume":"77","author":"Markman","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0190","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ygyno.2005.02.003","article-title":"Chemotherapy-induced changes of CA 125 in patients with epithelial ovarian cancer","volume":"97","author":"S\u00f8gaard","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0195","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1097\/00000421-199112002-00012","article-title":"Droloxifene-induced spikes of tumor markers predict benefit of therapy","volume":"14","author":"Kreienberg","year":"1991","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0200","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/annonc\/mdw238","article-title":"Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial","volume":"27","author":"Lindemann","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0205","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cca.2012.10.058","article-title":"Detection and monitoring of ovarian cancer","volume":"16","author":"Su","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.clinbiochem.2018.08.003_bb0210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2217\/fon.11.135","article-title":"Protein biomarkers of ovarian cancer: the forest and the trees","volume":"8","author":"Nolen","year":"2012","journal-title":"Future Oncol."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912018306659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912018306659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:53:32Z","timestamp":1757865212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912018306659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":42,"alternative-id":["S0009912018306659"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2018.08.003","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum human epididymis protein 4 vs. carbohydrate antigen 125 in ovarian cancer follow-up","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2018.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}